NCT07015333View on ClinicalTrials.gov

Case Review of Patients With Betel Nut-induced Oral Cancer Treated With Pembrolizumab and Cetuximab

CompletedOBSERVATIONAL
Enrollment

31

Participants

Timeline

Start Date

March 1, 2020

Primary Completion Date

November 1, 2024

Study Completion Date

December 1, 2024

Conditions
Oral Squamous Cell Carcinoma (OSCC)
Interventions
DRUG

pembrolizumab and cetuximab

Treatment of betel nut-induced oral cancer with pembrolizumab and cetuximab

Trial Locations (1)

96950

CHCC, Saipan

All Listed Sponsors
lead

Commonwealth Healthcare Corporation

OTHER

NCT07015333 - Case Review of Patients With Betel Nut-induced Oral Cancer Treated With Pembrolizumab and Cetuximab | Biotech Hunter | Biotech Hunter